How Retatrutide Controls Blood Sugar: The Triple-Hormone Mechanism

Introduction

Most diabetes medications work on one lever: insulin, glucose absorption, or appetite. Retatrutide is built differently. It activates three separate hormone receptors at once — GLP-1, GIP, and glucagon — each contributing to blood sugar control through a distinct biological pathway, rather than relying on a single mechanism turned up to maximum.

This isn't just a theoretical advantage. In TRANSCEND-T2D-1, the first completed Phase 3 trial testing retatrutide in people with type 2 diabetes, this triple-hormone approach produced HbA1c reductions of up to 2.0% — among the larger effect sizes seen in a diabetes drug trial — while simultaneously driving substantial weight loss in the same patients. Here's how each piece of the mechanism contributes, and what the actual trial data shows.

The Three-Hormone System Behind Blood Sugar Control

Blood sugar regulation in a healthy body is a continuous negotiation between several hormones. Insulin helps cells absorb glucose from the bloodstream after eating. Glucagon does roughly the opposite — it tells the liver to release stored glucose when you haven't eaten in a while. Incretin hormones like GLP-1 and GIP, released from the gut after meals, fine-tune both sides of that exchange.

In type 2 diabetes, this system breaks down in several ways at once: cells stop responding properly to insulin (insulin resistance), the pancreas works harder to compensate, and the incretin response that normally helps regulate post-meal glucose spikes becomes blunted. Retatrutide's design targets multiple points in this broken system simultaneously, rather than just one.

How Each Hormone Contributes

GLP-1: Glucose-Dependent Insulin Release

GLP-1 stimulates the pancreas to release insulin specifically when blood glucose is elevated — a property called glucose-dependence. This matters clinically because it's a major reason GLP-1-based drugs carry a much lower risk of hypoglycemia (dangerously low blood sugar) compared to older diabetes medications like sulfonylureas, which stimulate insulin release regardless of current glucose levels. GLP-1 also slows gastric emptying and reduces appetite, contributing to the weight loss side of the equation.

GIP: The Underappreciated Insulin Sensitizer

GIP was historically considered to have a blunted or even dysfunctional effect in people with type 2 diabetes. More recent research has shown that GIP receptor activation can still meaningfully improve insulin sensitivity, particularly in fat tissue, and that this effect is largely preserved even in established diabetes. Tirzepatide (marketed as Mounjaro for diabetes and Zepbound for weight loss) demonstrated this clinically by combining GLP-1 and GIP agonism and outperforming GLP-1-only semaglutide on glycemic control in head-to-head trials. Retatrutide builds on the same GLP-1/GIP foundation, then adds a third receptor.

Glucagon: Counterintuitive, But Additive

Glucagon's role is the least intuitive part of retatrutide's mechanism, since glucagon on its own raises blood glucose by signaling the liver to release stored sugar. In retatrutide, glucagon receptor activation is balanced against the glucose-lowering effects of GLP-1 and GIP, and its primary contribution is metabolic rather than glycemic: it increases energy expenditure and accelerates fat oxidation. The resulting weight loss then improves insulin sensitivity throughout the body — creating an indirect, second-order glucose-lowering effect that compounds the direct hormonal action of GLP-1 and GIP.

The Clinical Evidence

The mechanism above isn't just theoretical — TRANSCEND-T2D-1, the first Phase 3 trial of retatrutide specifically in type 2 diabetes, confirmed it translates into real glycemic improvement.

For the full breakdown of this trial, including baseline patient characteristics, side effect data, and how the results compare to other GLP-1-class drugs, see our full TRANSCEND-T2D-1 breakdown.

Why Weight Loss and Glucose Control Reinforce Each Other

One of the clinically important features of retatrutide's mechanism is that its two main effects — glucose control and weight loss — aren't independent. They feed into each other.

Excess fat tissue, particularly visceral fat around the abdominal organs, releases inflammatory signaling molecules that directly interfere with insulin's ability to do its job. This is a core driver of insulin resistance. As weight comes off, that inflammatory burden decreases, and insulin sensitivity improves — independent of any direct drug effect on insulin signaling.

This creates a reinforcing cycle: retatrutide's appetite-suppressing and metabolism-boosting effects drive weight loss, weight loss improves insulin sensitivity, improved insulin sensitivity allows blood glucose to drop further, and lower glucose reduces the metabolic stress that was driving further weight gain or treatment resistance. In TRANSCEND-T2D-1, this is part of why glycemic improvements continued alongside ongoing weight loss through the full 40-week trial period rather than plateauing early.

How This Compares to Other Diabetes Medications

The pattern that emerges across this drug class is consistent: adding receptor targets (single → dual → triple) doesn't necessarily produce dramatically larger HbA1c reductions, since glucose control by this mechanism appears to have a practical ceiling that GLP-1/GIP dual agonism already approaches. What does change substantially is weight loss — retatrutide's third receptor (glucagon) adds metabolic and weight effects without sacrificing the glycemic control achieved by the first two. For a full head-to-head comparison including weight loss figures, see our vs Tirzepatide vs Semaglutide guide.

Hypoglycemia Risk

Because GLP-1's insulin-stimulating effect is glucose-dependent, retatrutide carries a low intrinsic hypoglycemia risk when used alone or alongside metformin — neither of which forces insulin release independent of actual blood sugar levels.

That risk profile changes when retatrutide is combined with medications that do act independently of glucose levels. In TRANSCEND-T2D-1, participants were largely treatment-naive (85% had not used antihyperglycemic medication in the 90 days before enrollment), so the trial doesn't directly characterize hypoglycemia risk when retatrutide is added to existing insulin or sulfonylurea regimens. Based on the established pharmacology of GLP-1-class drugs generally, patients on insulin or sulfonylureas who start a GLP-1/GIP/glucagon agonist typically need dose adjustments to these other medications under physician supervision, to avoid additive glucose-lowering effects pushing blood sugar too low.

A Note on "Diabetes Remission"

In TRANSCEND-T2D-1, a meaningful share of patients — 37-40% in the 9mg and 12mg groups, compared to 14% on placebo — reached an HbA1c below 5.7%, the threshold generally considered within the normal, non-diabetic range, while on treatment.

It's worth being precise about what this does and doesn't mean. Clinical diabetes remission is typically defined as maintaining normal glucose levels for at least three months without diabetes medication. The TRANSCEND-T2D-1 results describe glycemic normalization while actively on retatrutide, not remission in that stricter sense. Whether these improvements would persist after stopping treatment hasn't been tested in this trial, and based on what's known about GLP-1-class drugs generally, glucose control typically declines toward baseline within months of discontinuation unless weight loss is independently maintained through diet and exercise.

Conclusion

Retatrutide's blood sugar benefits come from a genuinely different mechanism than most existing diabetes drugs — three hormone systems working in coordination rather than one pathway pushed to its limit. GLP-1 provides safe, glucose-dependent insulin stimulation; GIP adds insulin-sensitizing effects even in established diabetes; and glucagon, despite raising glucose on its own, contributes net metabolic benefit through weight loss that reinforces glycemic improvement.

TRANSCEND-T2D-1 confirmed this mechanism translates into real clinical results: up to 2.0% HbA1c reduction, alongside 16.8% weight loss, in the first completed Phase 3 trial of retatrutide in people with type 2 diabetes. For the complete trial breakdown and how these results compare across populations, see our complete retatrutide guide.

Sources

• Bajaj HS, et al. "Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial." The Lancet, 2026.
• Rosenstock J, Frias J, Jastreboff AM, et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes." The Lancet, 2023;402:529-544.
• Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." New England Journal of Medicine, 2023.
• Mather KJ, Mari A, Heise T, et al. "Effects of tirzepatide vs semaglutide on β-cell function, insulin sensitivity, and glucose control during a meal test." Journal of Clinical Endocrinology & Metabolism, 2024;109:3046-3054.